Fast Locator 2011-2012: UPM Pharmaceuticals, Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: UPM Pharmaceuticals, Inc.



UPM Pharmaceuticals® is a Baltimore-based, independent provider of contract drug development, cGMP manufacturing and analytical testing services. We specialize in oral routes of administration with a focus on solid dosage forms. With our commitment to efficiency, timeliness and flexibility, we deliver industry-savvy, customer-focused services. Our scientists have extensive experience with product development challenges such as low dose content uniformity, high dose compressibility and controlled drug release rates. UPM has be helping clients successfully navigate the drug development continuum for the past two decades. Our extensive equipment train, experienced professional staff and our commitment to quality translates into success for each and every project.


Regions where services are provided:

Asia, North America, Europe, Latin America, Japan, & Middle East


Outsourcing serivces provided:

Development and Phase I/IICTM

  • Drug delivery
  • Solid dose, semisolids, and liquids development
  • Process development-small molecule

Commercial Manufacturing

  • Ingredient processing
  • Semisolids and liquids
  • Solid dosage forms
  • Specialty dosage forms

Analytical Services

  • Chemistry and stability
  • Particle characterization

Packaging and Logistics

  • Clinical labels
  • Clinical packaging and distribution

Website:

www.upm-inc.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here